Aim. To assess impact of pharmacist managed anticoagulation management service on Egyptian atrial fibrillation patients' anticoagulation management, incidence and severity of bleeding events and thromboembolic events, incidence of warfarin drug and food interactions.
groups and final evaluation included; percentage time in therapeutic range (TTR), anticoagulation knowledge assessment questionnaire (AKA), side effect, warfarin drug and food interaction reporting.
Results.
Groups were compared and there was no significant difference between them at baseline. After 6 months, study group's TTR levels were significantly (p< 0.001) higher as compared to control group. The patients' AKA score was significantly (p< 0.001) increased in study group compared to control group. Study group had a significantly lower frequency of bleeding (p<0.001) and no significant difference in thromboembolic (p= 0.154) or nonspecific episodes (p= 0.303) versus control group, Study group had a significantly lower frequency of warfarin drug interactions (p= 0.004) and no significant difference in frequency of warfarin food interaction (p= 0.17) versus control group.
Conclusion. Pharmacist managed anticoagulation management service improved
patients' INR control, frequency of acute complications, frequency of warfarin drug interactions and patients' level of anticoagulation education.
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Introduction:
Atrial Fibrillation (AF) is a heart rhythm disorder of the atria associated with deadly and debilitating consequences including heart failure, stroke, poor mental health, reduced quality of life and death (Stewart et al., 2002) . The prevalence of atrial fibrillation is increasing particularly in developing countries due to the aging population Many patients have a poor understanding of AF as a disease and its pharmacotherapeutic requirements. In a study by Lip and colleagues, it was reported that 37% of documented chronic AF patients were unaware that they had AF and nearly half didn't know why they were taking warfarin. A similar number didn't know they were at risk of clots that could cause stroke. Sixty percent felt that their underlying condition (AF) was not severe. availability that lacks proper patient education, follow up and monitoring for adverse drug events. The current situation has initiated our proposal to investigate the impact of such service on patient outcome. Another obstacle to achieving good control of anticoagulation among atrial fibrillation patients in Egypt is the relatively poor structure and processes of care in government hospitals and primary health care units.
The role of pharmacists has changed dramatically over the past 30 years with a change in the pharmacy practice concept from being a product-oriented practice to a patientoriented one. The Pharmacist has become an integral member in the health care team. In Egypt, the clinical pharmacists' role in anticoagulation management service is still underutilized and under investigated.
The aim of the current study was to evaluate the role of a pharmacist managed anticoagulation management service on atrial fibrillation patients' INR control, frequency of acute complications, drug and food interactions and level of anticoagulation education.
Patients & methods:
Design:
prospective randomized controlled study, according to research ethics committee guidelines.
Setting:
Cardiology department, Ain Shams University Hospitals, Cairo.
Patients:
All patients presenting to the cardiology department were assessed for eligibility and present study was carried out From November 2012 to February 2014.
Inclusion criteria:
newly diagnosed AF patients, who received warfarin, aged 18-80 years, moderate to high risk of developing stroke.
Exclusion criteria:
patient with renal disorder or on renal dialysis, pregnancy or lactation, dementia, moderate to severe hepatic disorder, valvular heart disease, clinically significant active bleeding, recurrent DVT or PE. Eligible patients were randomly assigned to:
Control (routine medical care group):
30 patients were observed by the clinical pharmacist and evaluated at baseline, monthly and at study end.
Study (Pharmacist group):
30 patients subjected to a thorough clinical pharmacist anticoagulation management and were evaluated at baseline, monthly and at study end.
Methods:
All reported investigations in the current study have been carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000.The ethical committee of Ain Shams University approved the study. All patients were informed of study protocol and only those who consented to participate were enrolled.
A. Baseline Evaluation:
At enrollment, through a face to face interview, pharmacist gathered the following information for both groups: a full history taking (Medical, medication, family and social histories and demographic data), Laboratory data (INR, CBC, and and assessed anticoagulation knowledge items that are relevant to INR control with a total score of 15(AKA 2 score). Clinical pharmacist interviewed the patient through a face to face interview and allocated the score according to patients' answer.
Score allocation. Each question was provided with a model answer, and patients' scores were allocated according to coverage of model answers' contents (Table 1) . Baseline education:
For both groups:
-Patients were given the follow up side effects reporting card.
-The follow up card was used for patients' self -assessment and reporting of the frequency of bleeding, thromboembolic and non-specific events/ day during the 6 months period. The main events reported were; minor bleeding (bleeding gum, epistacsis), internal bleeding (bruises), major bleeding (haematepsis, blood in urine/stool/vomit), thromboembolic (DVT, leg change color/vessels appear, pulmonary embolism), non-specific (leg pain, leg swell, dyspnea, chest pain, hypotension, tachycardia, dizziness, headache, skin rash, nausea, and other).
The numbers of events were summed up to give the frequency of bleeding, thromboembolic and non-specific events.
-Patients were educated about using the follow up event card, the expected events & how to report them.
For the study group:
-Follow up events card education -A Structured anticoagulation education first was performed by the clinical pharmacist to cover the basic atrial fibrillation knowledge, warfarin use and common side effects, warfarin drug and food interactions.
B. Follow up assessment:
During the Patients in study group were additionally assessed for 1. Their educational level and education was reinforced as individually required by patients.
Stability of INR value in range and readjustment of warfarin dose if required.
Patients in control group were referred to their physician if the INR value was out of range to be adjusted by means of the physician.
C. End of study assessment:
After the 6 months of study duration, both groups were assessed for the following; 
D. Statistical methods
Data management and analysis were performed using Statistical Package for Social Sciences (SPSS) vs. 17. Numerical data were summarized using means and standard deviations or median & ranges. Categorical data were summarized as percentages. Comparisons between the two groups were done using the Mann-Whitney test. The Chi-square or the Fisher's exact tests for small sample size were used to compare between the groups with respect to categorical data. Repeated measures analyses of variance were done to study the differences between groups and change with time.
P-values are two-sided. P-values < 0.05 were considered significant and P-values < 0.001 were considered highly significant.
E. Materials (Drugs):
Warfarin: Marevan®, available in different strengths (1mg, 3mg and 5mg), uncoated tablets; each tablet contains warfarin sodium, lactose, maize starch, maize starch pregelatinised, purified water, and sodium starch glycolate and magnesium stearate, manufactured by GlaxoSmithKline, Egypt.
Results:
From November 2012 to February 2014 the present study was carried out on 60 non-valvular atrial fibrillation patients who fit the inclusion criteria and were randomly assigned to control or study group. All the 60 patients who started the study completed till the end of the study.
Baseline Evaluation
At baseline, both groups were comparable in their baseline parameters with no significant difference between them (Table 2) . 
After treatment evaluation a. Percentage time in therapeutic INR range (TTR %)
After 6 months of implementing pharmacist managed anticoagulation managed service, there was a significant difference in percentage TTR levels between the 2 groups. The study group's TTR% was higher than the control group with a high significant difference (p <0.001).
The mean (SD) TTR% was 38% (11%) for the control group versus 68% (8%) for the study group (Table 3 At baseline, there was no significant difference in the AKA 1 or AKA 2 scores between the 2 groups, while at the end of the study, there was a significant increase in AKA1 and AKA2 scores with time in both groups. The control group's scores increased with time but much less than the study group. The study group's scores significantly increased (p < 0.001) with time after the implementation of the anticoagulation management service (Table 3 and Figure2) . 
Number of events
The median number of events in the 6 months period was highly significantly lower (p<0.001) in the study group (4; range: 2-7) relative to the control group (5; range: 3-10) (Table 3) .
Frequency of bleeding events over 6 months
The median frequency of bleeding events over the 6 months period was significantly lower (p<0.001) in the study group (0.5; range: 0-4) relative to the control group (2; range: 0-9) (Table 3) .
Frequency of thrombo embolic events over 6 months
There was no significant difference (p=0.154) in the median frequency of thromboembolic events in the 6 months period between the study group (0; range: 0-0) relative to the control group (0; range: 0-2) (Table 3 ).
Frequency of non-specific events over 6 months
There was no significant difference (p=0.303) in the median frequency of non-specific events in the 6 months period between the study group (3; range: 1-5) relative to the control group (2; range: 0-10) (Table 3) . (Table 3 ).
e. Frequency of warfarin drug interaction:
The median frequency of warfarin drug interaction in the 6 months period was significantly lower (p=0.004) in the study group (0; range: 0-2) relative to the control group (0.5; range: 0-3) (Table 3 ).
f. Frequency of warfarin food interaction
There was no significant difference between both groups in the incidence of warfarin food interaction (Table 3 ).
g. Number of out of INR range reading
The mean number of out of INR range readings in the 6 months period was highly significantly lower (p<0.001) in the study group (3.4; SD= 1) relative to the control group (7.3; SD= 1.8) (Table 3 ).
h. Reasons of out of INR range reading
The median frequencies of Non-Compliance as a reason of out of INR range
reading is highly significantly lower in study group(0; range:0-2) than control group (2; range:0-4) ( Table 3) .
The median frequencies of Improper Dosing or testing as a reason of out of
INR range reading is highly significantly lower in study group(0; range:0-0) than control group (2; range:0-5) (Table 3) .
The median frequency of Warfarin drug interaction as a reason of out of INR
range reading is significantly lower in study group(0; range:0-2) than control group (1; range:0-3) (Table 3) .
4. There was no significant difference between study and control group in the median frequencies of Warfarin food interaction, Illness, Start dose and unknown as reasons of out of INR range readings (Table 3) . Poor knowledge leads to non-adherence to medication therapy, leading to poor INR control and negative outcomes (AntiCoagulation Europe, 2009).
Our study has assessed atrial fibrillation patients' basic knowledge and practice.
Both groups were not significantly different in their AKA1 and AKA2 scores at baseline. At the end of the study, the AKA1 and AKA2 scores increased in the pharmacist and control groups, yet the increase in the pharmacist managed group was significantly higher than the regular care group. Moreover, the increase of change in both scores from baseline was significantly higher in the pharmacist managed group versus the regular care.
Our results are in accordance with a prior prospective study of Lane et al. 
Conclusion:
The current study showed that pharmacist provided anticoagulation management service was associated with significantly higher % of TTR, higher levels of anticoagulation knowledge and practice and a lesser frequency of bleeding, thromboembolic events.
Hence, we recommend that pharmacist role in anticoagulation management service & education should be highly enforced and nationally implemented as it can contribute to more anticoagulation control, awareness and lesser complications.
